The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy  by Gonçalves, Leonor et al.
Neuropharmacology and analgesia
The inﬂuence of μ-opioid and noradrenaline reuptake inhibition
in the modulation of pain responsive neurones in the central amygdala
by tapentadol in rats with neuropathy
Leonor Gonçalves n, Lauren V. Friend, Anthony H. Dickenson
Neuroscience Physiology & Pharmacology, Medical Sciences Building, University College London, Gower St, London WC1E 6BT, UK
a r t i c l e i n f o
Article history:
Received 24 June 2014
Received in revised form
10 November 2014
Accepted 16 November 2014
Available online 6 January 2015
Keywords:
Rat
Tapentadol
Neuropathy
Right central amygdala
Opioid
Noradrenaline
a b s t r a c t
Treatments for neuropathic pain are either not fully effective or have problematic side effects. Combinations of
drugs are often used. Tapentadol is a newer molecule that produces analgesia in various pain models through
two inhibitory mechanisms, namely central μ-opioid receptor (MOR) agonism and noradrenaline reuptake
inhibition. These two components interact synergistically, resulting in levels of analgesia similar to opioid
analgesics such as oxycodone and morphine, but with more tolerable side effects. The right central nucleus of
the amygdala (CeA) is critical for the lateral spinal ascending pain pathway, regulates descending pain
pathways and is key in the emotional-affective components of pain. Few studies have investigated the
pharmacology of limbic brain areas in pain models. Here we determined the actions of systemic tapentadol on
right CeA neurones of animals with neuropathy and which component of tapentadol contributes to its effect.
Neuronal responses to multimodal peripheral stimulation of animals with spinal nerve ligation or sham
surgery were recorded before and after two doses of tapentadol. After the higher dose of tapentadol either
naloxone or yohimbine were administered. Systemic tapentadol resulted in dose-dependent decrease in right
CeA neuronal activity only in neuropathy. Both naloxone and yohimbine reversed this effect to an extent that
was modality selective.
The interactions of the components of tapentadol are not limited to the synergy between the MOR and α2-
adrenoceptors seen at spinal levels, but are seen at this supraspinal site where suppression of responses may
relate to the ability of the drug to alter affective components of pain.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Approximately 8% of the world population is affected by neuro-
pathic pain (Tzschentke et al., 2007). Treatment options include anti-
convulsants and antidepressants as well as opioids but overall, are
either not very effective (Fishbain, 2000), or the common side effects
are not well tolerated by patients (Katz and Benoit, 2005). Opioids,
for example, provide a good level of analgesia, but besides the
potential abuse (Kalso et al., 2004) and opioid-induced hyperalgesia
(Bannister and Dickenson, 2010), side effects (constipation, nausea,
sedation, respiratory depression) are common and impairing (Bruehl
et al., 2013). Often, combinations of drugs are used to increase
analgesia or reduce side-effects (Gilron et al., 2009).
Tapentadol is a recent drug with a dual mode of action that has
been shown to produce an analgesic effect in chronic pain in humans
(Hartrick and Rozek, 2011) and animals (Tzschentke et al., 2007),
acting centrally through two mechanisms: μ-opioid receptor (MOR)
agonism and noradrenaline reuptake inhibition (NRI), with the latter
leading to α2-adrenoceptor activation (Tzschentke et al., 2007).
Although each of the two components can produce analgesia
independently, their synergistic interaction allows a moderate action
of each, resulting in levels of analgesia similar to that of opioid
analgesics such as oxycodone and morphine, but with reduced opioid
load and so a more tolerable side effect proﬁle (Riemsma et al., 2011;
Schröder et al., 2011). Tapentadol action results, at least in part, from
its interaction with spinal MOR and enhancement of spinal noradre-
naline levels to activate α2-adrenoceptor inhibitions (Bee et al., 2011).
Relatively few analgesics have been studied on supraspinal struc-
tures and little is known about actions on areas involved in affective
components of pain. This is important since patients report not only
pain but reduced quality of life (ref). Supraspinally, the amygdala
(AMY), mainly the right CeA (Carrasquillo and Gereau, 2008) is
critically involved in the lateral spinal ascending pathways and in
regulation of descending pain pathways. The AMY is key in the
emotional-affective component of pain (Neugebauer et al., 2004;
Neugebauer et al., 2009) and the central nucleus of the amyg-
dala (CeA) has a foremost role, with a high number of nociceptive
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neurones (Neugebauer and Li, 2002) and strong responses to periph-
eral stimuli (Neugebauer et al., 2004). Activation of AMY neurones
happens mostly after aversive stimuli through multiple sensory
modalities (Fischer et al., 2003; Garrett and Maddock, 2001; Phan
et al., 2004; Phelps et al., 2001; Zald and Pardo, 2002) and includes
ongoing and evoked abnormal activity after neuropathy that dom-
inates in the right CeA (Gonçalves and Dickenson, 2012). In this latter
study, pregabalin was able to reduce neuronal activity in neuropathic
animals although the ability of the drug to act as an anxiolytic as well
as an analgesic complicates its effects.
In this study we aimed to determine if systemic tapentadol has an
effect on the responsivity of right CeA neurones of animals with
neuropathy and to clarify which component of this drug contributes
to its effect. In order to achieve this we recorded and analyzed the
activity of right CeA neurones of animals subjected to spinal nerve
ligation (SNL) or sham surgery, before and after two doses of
tapentadol. In addition, after the higher dose of tapentadol we
administered either the MOR antagonist naloxone or the α2-adreno-
ceptor antagonist yohimbine.
2. Material and methods
All experimental procedures used in this study were approved by
the UK Home Ofﬁce and followed the guidelines under the
International Association for the Study of Pain (Zimmermann,
1983). The electrophysiological data that resulted from these experi-
ments were obtained from naïve animals and animals subjected to
either sham or spinal nerve ligation surgery (SNL; Kim and Chung,
1992).
The numbers of animals used on this study were as follows: naïve
n¼8, sham n¼22, SNL (tapentadol) n¼21 and SNL (naloxone alone)
n¼4. From the 22 sham rats, 5 were recorded for extra 20min after
5 mg/kg tapentadol with no further treatment, 7 were injected with
naloxone and 10 injected with yohimbine. From the 21 SNL rats,
5 were recorded for extra 20 min after 5 mg/kg tapentadol with no
further treatment, 8 were injected with naloxone and 8 injected with
yohimbine.
2.1. Spinal nerve ligation
The spinal nerve ligation model (SNL) was induced through
surgery and performed, as ﬁrst described by Kim & Chung (1992),
in the lower left lumbar spinal region of Sprague–Dawley male
rats (Central Biological Services, University College London, Lon-
don UK), initially weighing 130–150 g. Brieﬂy, selective tight
ligation of spinal nerves L5 and L6 is performed with 6–0 silk
thread under isoﬂuroane (1.5–1.7%) delivered in a gaseous mix of
Fig. 1. Sections of the atlas representing the placement of the recordings. The recordings (red dots) were located between 2.40mm and 2.64mm caudal, 7.40 mm and 8.50mmventral
and 3.6 mm and 5mm lateral (to the right) from bregma. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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N2O (66%) and O2 (33%). The sham procedure is identical to similar
to the normal SNL surgery, but omits the ligation of the nerves.
2.2. Electrophysiology
Since in a previous study we showed that CeA neuronal evoked
activity is increased and stable at 14 days after SNL surgery (Gonçalves
and Dickenson, 2012), single neurones in the CeA were recorded
extracellularly with parylene coated tungsten electrodes (A-M Systems,
USA) on post-operative days 14–17, using the stereotaxic coordinates
(Ji and Neugebauer, 2009): 1.6–3.2 mm caudal, 3.8–4.4 mm lateral and
7.8–8.6 mm ventral to bregma (Fig. 1). Only neurones from the right
CeA were recorded in this study, given that previous studies showed
that pain processing seems to be lateralized to right the AMY, and right
CeA neurones have higher activity than left CeA neurones in inﬂam-
matory, arthritic and neuropathic pain (Carrasquillo and Gereau, 2008;
Ji and Neugebauer, 2009; Gonçalves and Dickenson, 2012).
The animals were ﬁrst placed in a induction box and anesthetized
with isoﬂuorane (5%) delivered in a gaseous mix of N2O (66%) and
O2 (33%), were then transferred to a nose cone (receiving isoﬂuorane
(3%) delivered in the same gaseous mix) in order to perform a
tracheotomy, after which they received the isoﬂuorane (1.5–1.7%) and
gaseous mix of N2O and O2 directly to the trachea, through a tube
connected to the anesthetic and gases system. The animals were then
maintained at this level of anesthesia with areﬂexia for the entire
duration of the experiment.
Afterwards, the animals were ﬁxed in a stereotaxic device and,
after the skull was exposed, CeA coordinates were calculated after
bregma (Ji and Neugebauer, 2009). Finally, a small craniotomy was
performed with a drill and the dura matter removed, exposing the
brain. To be considered for the experiment, neurones had to ﬁre
spontaneously and constantly for at least 20 min, after which two
rounds of spontaneous and evoked activity were recorded (the
average of these two rounds was considered to be baseline activity).
On SNL and sham animals, spontaneous and stimuli-activity of
right CeA neurones (one per animal) were recorded and analyzed
before (baseline) and 10, 20, 40 and 60min after each dose of
tapentadol, and 10 and 20min after naloxone or yohimbine injection.
In a separated set of naïve and SNL animals, the same recordings were
made before and 10, 20, 40 and 60min after naloxone administration.
The following stimuli were applied for a period of 10 s (separated by a
40 s interval; Goncalves and Dickenson, 2012): von Frey ﬁlaments
(0.008 g, 4.0 g, both innocuous and 60 g, noxious), cold (4 1C, acetone
test) and heat (48 1C, constant water jet) applied on both hindpaws,
and controlled pinch of right hindpaws, tail and right ear.
Data are captured by a CED 1401 interface coupled to a Pentium
computer with Spike 2 software (Cambridge Electronic Design;
PSTH and rate functions) and posteriorly analyzed.
2.3. Drug administration
In this study three different drugs were used: tapentadol HCl
(MOR agonist and noradrenaline reuptake inhibitior; Grunenthal
GmbH, Aachen, Germany), naloxone HCl (MOR antagonist; Sigma
Chemie, Deisenhofen, Germany) and yohimbine HCl (α2-adreno-
ceptor antagonist, Sigma Chemie, Deisenhofen, Germany).
An injection of tapentadol 1 mg/kg was ﬁrst administered via
subcutaneous injection in the scruff of the back of the neck of each
animal and activity of one spontaneously ﬁring neurone is fol-
lowed for over 60 min, with tests carried out at 10, 20, 40 and
60 min. 70 min after the ﬁrst dose, a second (higher) dose of
tapentadol (5 mg/kg) is administered in the same manner, and
tests carried out at the same time points. One 70 min after the
higher dose of tapentadol either the recordings are prolonged for
an extra 20 min, with tests performed at 10 and 20 min (control
for the maintenance of the effect of the high dose of tapentadol for
a longer period), or one antagonist (naloxone 5 mg/kg or yohim-
bine 5 mg/kg) per animal is injected subcutaneously, and tests
carried out after 10 and 20 min. Drug does were based on those
previously shown to be effective at spinal levels (Bee et al., 2011).
2.4. Statistical analysis
Unless stated otherwise, all comparisons were analyzed through
repeated measures ANOVA test and Bonferroni Post Hoc using IBM
SPSS Statistics software (version 21.0.0.0).
3. Results
3.1. Spontaneous and evoked neuronal activity in the CeA of SNL rats
is signiﬁcantly higher than in sham rats
Right CeA neuronal activity in SNL rats is signiﬁcantly higher than
in sham rats in both spontaneous and evoked conditions (data not
shown). As previously demonstrated (Gonçalves and Dickenson,
2012), baseline spontaneous activity in the right CeA neurones was
6.82–11.13 Hz for SNL rats but only 1.52–3.43 Hz for sham rats.
Neuronal responses to different stimuli were also different, being
greater after nerve injury: 6.7–11.69 Hz for SNL and 3.01–4.58 Hz
for sham animals after 0.008 g von Frey; 8.59–11.16 Hz for SNL and
2.16–4.83 Hz for sham animals after 4 g von Frey; 8.48–11.85 Hz for
SNL and 2.21–4.28 Hz for sham animals after 60 g von Frey;
10.39–14.47 Hz for SNL and 3.04–4.60 Hz for sham animals after
cold; 11.48–14.10 Hz for SNL and 3.18–4.55 Hz for sham animals after
heat; 10.93–15.245 Hz for SNL and 3.07–4.40 Hz for sham animals
after paw pinch; 12.34–15.25 Hz for SNL and 2.86–3.94 Hz for sham
animals after tail pinch; and 11.12–14.16 Hz for SNL and 2.70–4.72 Hz
for sham animals after ear pinch.
3.2. Evoked neuronal activity in the right CeA is signiﬁcantly higher
than spontaneous activity in SNL animals
Responses evoked by all stimuli but 0.008 g von Frey were sig-
niﬁcantly higher than spontaneous activity recorded on the CeA of SNL
animals during baseline (Fig. 2 A and B). Statistically analysis showed
differences both in the group that subsequently received naloxone
(Fig. 2 A; 4 g von Frey-evoked activity P¼0.049, 60 g von Frey-evoked
activity P¼0.048; cold-evoked activity P¼0.042, heat-evoked activity
P¼0.008, paw pinch-evoked activity P¼0.020, tail pinch-evoked
activity P¼0.043, ear pinch-evoked activity P¼0.019) and the group
that subsequently received yohimbine (Fig. 2B; 4 g von Frey-evoked
activity P¼0.047, 60 g von Frey-evoked activity P¼0.013; cold-evoked
activity P¼0.048, heat-evoked activity P¼0.034, paw pinch-evoked
activity P¼0.014, tail pinch-evoked activity P¼0.019, ear pinch-
evoked activity Po0.001).
These changes were produced by the neuropathy as there were no
statistically signiﬁcant differences between spontaneous and evoked
activity in right CeA neurones of sham animals (Fig. 2 C and D). For
this reason, all the subsequent analysis were performed only on
spontaneous activity values for this group.
3.3. Tapentadol and antagonists have different effects on
spontaneous activity of CeA neurones in SNL and sham animals
3.3.1. Effect of two doses of tapentadol and subsequent
administration of antagonist on SNL animals
Systemic administration of 1 mg/kg tapentadol results in an
inhibition of neuronal activity of CeA neurones only in SNL animals
that did not reach signiﬁcance, while 5 mg/kg tapentadol result in a
greater and enduring inhibition of the same activity (Fig. 3 A and B). In
both groups the higher dose of tapentadol signiﬁcantly reduced
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neuronal activity (RM ANOVAwith Bonferroni pairwise comparisons):
P¼0.045 for naloxone group (Fig. 3 A) and P¼0.032 for the yohimbine
group (Fig. 3B). Both antagonists completely reversed the effect of
tapentadol, as shown by the lack of difference between baseline
activity and activity recorded after either naloxone (P¼0.931) or
yohimbine (P¼1.000).
Thus, tapentadol signiﬁcantly inhibited and spontaneous activities
of these neurones and both antagonists reversed these effects, in that
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Fig. 2. Comparison between spontaneous and evoked activities at baseline. SNL animals subsequently injected with tapentadol and naloxone (A) or yohimbine (B) showed
signiﬁcant differences between spontaneous activity and reponses to 4 g and 60 vonFrey, cold, heat, paw, tail and ear pinch. In sham animals there were no differences
between spontaneous and evoked activity (C and D) n, nn, nnnPo0.05, 0.01 and 0.001 for signiﬁcant difference between spontaneous and evoked activity. Mean7S.E.M.
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Fig. 3. Effect of 1 and 5 mg/kg tapentadol and subsequent naloxone or yohimbine on spontaneous activity of SNL and sham animals. (A) 5 mg/kg tapentadol administration
reduces SNL spontaneous activity, which is then reversed by 5 mg/kg naloxone. (B) 5 mg/kg tapentadol administration reduces SNL spontaneous activity, which is then
reversed by 5 mg/kg yohimbine. (C, D) Tapentadol did not have a signiﬁcant effect on spontaneous activity of sham animals. However, naloxone resulted in a signiﬁcant
increase of activity (C), as did yohimbine, although to a lesser extent (D). nPo0.05 for signiﬁcant difference between baseline and post-tapentadol administration.
#, ##Po0.05, 0.01 for signiﬁcant difference between activity before and after naloxone or yohimbine. Mean7S.E.M.
L. Gonçalves et al. / European Journal of Pharmacology 749 (2015) 151–160154
responses post-naloxone or post-yohimbine were no longer signiﬁ-
cantly different from the pre-tapentadol control values.
3.3.2. Effect of two doses of tapentadol and subsequent
administration of antagonist on sham animals
Tapentadol did not have a signiﬁcant effect on the spontaneous
activity of CeA neurones in sham animals (Fig. 3 C and D). However,
naloxone (Fig. 3 C) resulted in a signiﬁcant increase of activity relative
to baseline (P¼0.005), 1 mg/kg (P¼0.001) and both 5 mg/kg tapenta-
dol (P¼0.001) and yohimbine (Fig. 3D) resulted in a signiﬁcantly
higher activity relatively to baseline (P¼0.016), suggesting ongoing
opioid and noradrenergic tone.
3.3.3. Comparison between sham and SNL neuronal activity at
baseline and after naloxone or yohimbine (post-tapentadol)
Baseline spontaneous activity of CeA neurones of SNL animals is
signiﬁcantly higher than the same activity in sham animals (P¼0.016,
Fig. 4 A; Po0.001, Fig. 4B). After naloxone (Fig. 4 A) or yohimbine
(Fig. 4B), spontaneous activity of both SNL and sham animals was also
signiﬁcantly higher than baseline spontaneous activity of sham
animals (SNL Po0.001 and sham P¼0.019 after naloxone; both SNL
and sham P¼0.003 after yohimbine), but not different from the same
activity in SNL animals. Comparisons of these data were analyzed
through Two-Way ANOVA tests and Bonferroni Post Hoc using IBM
SPSS Statistics software (version 21.0.0.0).
3.4. Evoked activity of CeA neurones in SNL animals is affected by
tapentadol and antagonists
All values presented here and in the related graphs (Figs. 3 and 4)
refer to the evoked responses minus its respective spontaneous
activity. Since there was no signiﬁcant difference between sponta-
neous activity and responses to the lowest mechanical stimulus,
0.008 g von Frey (Fig. 2A and B; see above), the results from the latter
are not shown.
Neuronal CeA activity before and after tapentadol is presented
separately for each of the groups of SNL animals that received
either naloxone (Fig. 5) or yohimbine (Fig. 6). This resulted in
different statistical results for each of the groups, with both groups
showing a clear effect of tapentadol on spontaneous activity and
responses to 60 g von Frey (Fig. 5 A and 6 A), paw (Figs. 5E and 6E),
tail (Fig. 5 F and 6 F) and ear (Fig. 5 G and 6 G) pinch, all intense
mechanical noxious stimuli.
3.4.1. Effect of two doses of tapentadol and subsequent
administration of naloxone
Tapentadol signiﬁcantly reduced neuronal responses of the nalox-
one group to 60 g von Frey (P¼0.003 after 1 mg/kg and P¼0.006 after
5 mg/kg; Fig. 5B), paw pinch (P¼0.029 after 1 mg/kg and P¼0.016
after 5 mg/kg; Fig. 5E), tail pinch (P¼0.049 after 5 mg/kg; Fig. 5 F) and
ear pinch (P¼0.007 after 1 mg/kg and Po0.001 after 5 mg/kg;
Fig. 5 G). Naloxone reverses the effect that tapentadol has in these
evoked activity, shown by the lack of signiﬁcant difference, between
baseline and post-naloxone responses to 60 g von Frey (P¼1.000), tail
pinch (P¼1.000), paw pinch (P¼0.199) and ear pinch (P¼0.072).
3.4.2. Effect of two doses of tapentadol and subsequent
administration of yohimbine
Tapentadol signiﬁcantly reduced neuronal responses in the yohim-
bine group to 4 g von Frey (P¼0.011 after 1 mg/kg and P¼0.002 after
5 mg/kg; Fig. 6 A), 60 g von Frey (P¼0.009 5mg/kg; Fig. 6B), cold
(P¼0.009 after 1 mg/kg; Fig. 6 C), heat (P¼0.009 after 1 mg/kg and
P¼0.005 after 5 mg/kg; Fig. 6D), paw pinch (P¼0.002 after 1 mg/kg
and P¼0.001 after 5 mg/kg; Fig. 6E), tail pinch (P¼0.013 after 1 mg/kg
and P¼0.012 after 5 mg/kg; Fig. 6 F) and ear pinch (P¼0.011 after
1 mg/kg and Po0.001 after 5 mg/kg; Fig. 6 G). Yohimbine reversed
the effect of tapentadol on the responses of CeA neurones to 4 g and
60 g von Frey, heat, tail and ear pinch (P¼1.000 between baseline and
post-yohimbine; Fig. 6 A, B, D, F and G). The reversal was observed on
the responses to cold (P¼0.840 between baseline and post-yohim-
bine; Fig. 6 C) on the responses to paw pinch (P¼0.092 between
baseline and post-yohimbine; Fig. 6E).
Control studies veriﬁed that the effects of the antagonists were not
due to the effects of tapentadol wearing off since the effects of 5 mg/kg
were maintained for times longer than the antagonist studies.
3.5. Full raw recording of a single SNL CeA neurone time matched to
the overall population results from Fig 3D
As expected, the overall SNL population neuronal activity of (Fig. 7,
bottom graph) presents the same pattern of activity of a typical
individual SNL neurone (Fig. 7, top graph). Neuronal activity is high at
baseline (before Tap1), shows a slight decrease after administration of
tapentadol 1 mg/kg (Tap1) followed by an increase just before the
administration of tapentadol 5 mg/kg (Tap5), after which neuronal
activity becomes decreased in a stronger and more permanent
manner. Injection of antagonist (naloxone) results in an increase of
neuronal activity to values similar to baseline. The very high and
usually isolated lines represent interference, which is subtracted from
neuronal activity values in a post-recording analysis.
4. Discussion (1543/1500)
Neuroplasticity in the right CeA of animals in pain models
(Neugebauer and Li, 2002; Ji and Neugebauer, 2009), including
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Fig. 4. Comparison between SNL and sham CeA neuronal spontaneous activities at baseline and after naloxone or yohimbine. SNL and sham animals given tapentadol and
naloxone (A) or yohimbine (B) showed signiﬁcantly higher activity than spontaneous neuronal activity of sham animals at baseline. Spontaneous activity of neurones in the
CeA of SNL animals at baseline was also given signiﬁcantly higher activity than spontaneous neuronal activity of sham animals at baseline (A, B). n, nn, nnnPo0.05, 0.01 and
0.001 for signiﬁcant difference between sham baseline activity and any other of the 3 groups. Mean7S.E.M.
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neuropathic pain (Gonçalves and Dickenson, 2012), is likely to play
an important role in chronic pain and associated emotional
comorbidities (Gonçalves et al., 2008). We found that systemic
tapentadol, a MOR-NRI effective in patients with neuropathy,
osteoarthritis and low back pain (Games and Hutchison 2013;
Kavanagh et al., 2004), reduces spontaneous and evoked activity of
right CeA neurones in animals with neuropathy. We also deter-
mine that the two components of the inhibitory effects of
tapentadol (MOR producing opioid receptor activation and NRI
leading to α2-adrenoceptor activation) have differential effects on
spontaneous and stimuli-evoked activities. The action of tapenta-
dol was entirely dependent on the presence of nerve injury, since
there was no inhibitory effect in sham animals, suggestive that the
neuronal responses and pharmacological substrates in the amyg-
dala were highly linked to a persistent pathophysiological state.
Both the MOR and NRI components interact with important pain
inhibiting systems. Noradrenaline results in acute antinociception in
normal and neuropathic pain states through activation of α2-adreno-
ceptors, which decrease neurotransmitter release onto spinal dorsal
horn neurones (Eisenach, 1999). Accordingly, the α2-adrenoceptor
agonist dexmedetomidine inhibits acetylcholine release in spinal cord
(Obata et al., 2005). Drugs such as amitryptiline, duloxetine and
clonidine are often used to treat chronic neuropathic pain. These
drugs either activate, augment, or mimic the descending
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Fig. 5. Effect of 1 and 5 mg/kg tapentadol and subsequent naloxone administration on evoked activity of SNL animals. Spontaneous activity was subtracted from the
corresponding total activity after stimulation in order to obtain the real responses to stimuli. 1 and 5 mg/kg tapentadol and naloxone have no signiﬁcant effect on the
responses to 4g vonFrey (A), cold (C) and heat (D) stimulation. Responses to 60 g von Frey (B), paw pinch (E), and ear pinch (G) were signiﬁcantly reduced by 1 and 5 mg/kg
tapentadol and this effect was reversed by naloxone. Responses to tail pinch (F) were signiﬁcantly reduced by 5 mg/kg tapentadol and this effect was reversed by naloxone.
n, nn, nnn,Po0.05, 0.01 and 0.001 for signiﬁcant difference between baseline and post-tapentadol administration. Mean7S.E.M.
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noradrenergic pathway, stimulating spinal α2-adrenoceptors resulting
in analgesia (Xu et al., 1992; Xu et al., 1997; De Felice et al., 2011).
Here, the higher dose of tapentadol resulted in inhibition of
spontaneous and evoked activity of CeA neurones in SNL animals.
Although the effects of tapentadol were statistically signiﬁcant on the
responses to some stimuli only in the yohimbine group (Fig. 6 A, C
and D), there is a clear trend also on the naloxone group to lower
responses after tapentadol. Sham animals neuronal activity after
stimulation was not different from spontaneous activity, as described
before (Gonçalves and Dickenson, 2012); this spontaneous activity
was also not different before and after tapentadol administration
(Fig. 3 C and D), implicating that tapentadol affects CeA neuronal
activity only in the presence of neuropathy. While sham animals
neuronal activity at baseline is signiﬁcantly different from SNL
animals baseline, after naloxone and yohimbine spontaneous activity
is increased to values similar to activity in SNL animals (Fig. 4).
Both components of tapentadol have been implicated in endogen-
ous control of neuropathic pains. After nerve injury the modulating
effects of α2-adrenoceptors on spinal processing is lost (Rahman et al.,
2008). De Felice et al. (2011) reported a marked protective role of
noradrenergic systems in controlling the behavioral consequences of
SNL neuropathy, and Xu et al. (1992) described a similar role of MORs
after spinal cord injury. Shifts in the MOR-NRI components of
tapentadol are seen in behavioral tests of mechanical hypersensitivity
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Fig. 6. Effect of 1 and 5 mg/kg tapentadol and subsequent yohimbine administration on evoked activity of SNL animals. Spontaneous activity was subtracted from the
corresponding total activity after stimulation in order to obtain the real responses to stimuli. Responses to 4 g vonFrey (A), heat (D), tail (F) and ear (G) pinch were reduced by
1 and 5 mg/kg tapentadol and this effect was completely reversed by yohimbine. (B) Responses to 60 g von Frey were signiﬁcantly reduced by 5 mg/kg tapentadol and this
effect was completely reversed by yohimbine. (C) Responses to cold were signiﬁcantly reduced by 1 mg/kg tapentadol and this effect was almost completely reversed by
yohimbine. (E) Responses to paw pinch were signiﬁcantly reduced by 1 and 5 mg/kg tapentadol and this effect was partially reversed by yohimbine. n, nn, nnnPo0.05, 0.01
and 0.001 for signiﬁcant difference between baseline and post-tapentadol administration. Mean7S.E.M.
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in nerve injury models where yohimbine was much more effective
than naloxone in reversing the analgesic effect of tapentadol
(Tzschentke et al., 2007). In SNL and sham animals, atipamezole
(α2-adrenoceptor antagonist) or naloxone administered spinally
almost fully reversed tapentadol effects on all spinal neuronal
responses, suggested to be a reﬂection of the essential synergy
between the two components of tapentadol with a shift towards a
greater noradrenergic component after nerve injury (Bee et al., 2011).
In sham animals, using these spinal sensory neuronal measures, the
drug was effective. Here at higher CNS levels, and perhaps related to
limbic pain processes, the drug lacked effects in sham animals and the
antagonism studies after neuropathy weremore complex. Thus, in SNL
animals, while naloxone fully reversed 5 mg/kg tapentadol effects on
spontaneous activity (Fig. 3 A), and activity evoked by 60 g von Frey
and tail pinch (Figs. 2 and 3D), it failed to completely reverse the
responses of these neurones to cold, heat and ear pinch and it had no
effect on responses to paw pinch. On the other hand, yohimbine
administration reversed to baseline values of CeA responses to
virtually all stimulation and spontaneous activity to values slightly
below to baseline. This indicates that, in the presence of neuropathy,
either NRI or MOR components alone can control spontaneous activity
and responses to 60 g von Frey and tail pinch. In contrast, synergy
between NRI and MOR seems to be essential for the effect of
tapentadol on responses to cold, heat and ear pinch. The NRI
component alone underlies inhibition of neuronal responses to paw
pinch by tapentadol.
Spinally, the same doses of systemic tapentadol reduce mechanical,
thermal and electrical-evoked responses of dorsal horn neurones of
both SNL and sham rats dose-dependently (Bee et al., 2011). As the
doses and time-courses were similar in the brain and spinal cord, the
decreased activity observed in the CeA might be consequence of
inhibition of ascending activity by tapentadol acting spinally. How-
ever, since CeA receives dense ascending noradrenergic innervation
(Zardetto-Smith and Gray, 1990; Tully et al., 2007) and has a high
density of α2-adrenoceptors (Talley et al., 1996) and MORs (Mansour
et al., 1995; Poulin et al., 2006), the premise that tapentadol might be
acting directly in the AMY through NRI cannot be ruled out.
The same is true for the opioid component. MORs are densely
located in the amygdala, playing an important role in reversing
mechanical hypersensitivity following nerve injury (Martin et al.,
2011). μ-opioid agonist binding in the amygdala and ventral
midbrain decreases after chronic nerve injury (Martin et al., 2011;
Narita et al., 2006), changes thought to contribute to the establish-
ment and maintenance of chronic pain. Whilst intra-amygdalar
Fig. 7. Typical full recording (raw data) of a single SNL CeA neurone and the overall population results from Fig. 1D. Values of ﬁring per second (Hz) are represented on the
y-axis and time is represented on the x-axis. The upper graph represents the raw data, where the black bars at the top represent one test each. Interference is subtracted
when the data is extracted. The lower graph shows the effects of the same pharmacological study on the all population of neurones.
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administration of opioids results in analgesia through MOR activa-
tion (Ozaki et al., 2003), opioid agonists also inhibit the release of
noradrenaline in the amygdala (Wilson and Junor, 2008). Whatever
the case, the ability of tapentadol to modulate this limbic activity is
very different from its spinal actions. In the spinal cord, the MOR
and NRI components are different and the absolute dependency on
nerve injury for its action is not present.
AMY is highly active during exposure to emotional, high arousing
or motivational stimuli (Kawahara et al., 2004; Adolphs et al., 2000;
Cahill et al., 1996). Speciﬁcally, exposure to different aversive sensory
modalities (Fischer et al., 2003; Phan et al., 2004; Zald and Pardo,
2002), including unpleasant interoceptive or painful stimulation con-
sistently activates AMY neurones (Cahill et al., 2000). The AMY has a
particular important role in the strengthening and consolidation of
long-term emotional memory (Adolphs et al., 2000; Paré, 2003), and
noradrenaline is essential to complete this role (McGaugh et al., 1996;
McGaugh, 2000; Quirarte et al., 1997). Moreover, systemic or intra-
amygdalar administration of opioid receptor agonists and antagonists
respectively impair and enhance memory retention (Baker and Kim,
2004; Ferry et al., 1999), indicating that opioids are of functional
signiﬁcance in the regulation of emotional learning and memory
(Fanselow and Bolles, 1979), as is noradrenaline (Ferry and
McGaugh, 1999; Quirarte et al., 1997). The overlap between the
MOR-NRI mechanisms in pain modulation may extend to emotional
memory, and this should be looked into in future experiments.
In addition to the synergy between the μ-opioid and α2-
adrenoceptor components of the actions of the drug, there is also
a synergy between the spinal and supraspinal actions of the drug
(Schröder et al., 2011). Not only would a single antagonist interfere
with this interaction, but the effects of blocking spinal μ-opioid and
α2-adrenoceptor function spinally may be different at supraspinal
sites, as shown. Since tapentadol and the antagonists were given
systemically they could act on spinal and brain μ-opioid and α2-
adrenoceptor systems. Previous studies and our present results
suggest that the balance of the opioid and noradrenergic compo-
nent of tapentadol vary with models and persistence of the pain
and CNS sites. The inhibition of noradrenaline release in the
amygdala by opioid agonists (Kawahara et al., 2004) might explain
why the NRI component is even more predominant at spinal levels
where morphine does not alter noradrenaline levels and the ability
of tapentadol to elevate noradrenaline levels is not seen in sham
animals (Meske et al., 2014). The balance in drugs pharmacological
actions will likely vary, depending on the CNS area. This and all the
similarities between pain and memory mechanisms lead to the
consideration of chronic pain as a disease of CNS plasticity (Price
and Ghosh, 2013). The ability of tapentadol to improve quality of life
in pain patients may relate to its ability to modulate amygdala
activity. Indeed, as we have recently reported in detail (Gonçalves
and Dickenson, 2012), there is a time related shift from left to right
amygdala after neuropathy in both ongoing and evoked activities of
CeA neurones.
5. Conclusion
CeA activity of SNL rats is decreased by systemic administration of
tapentadol, and this is reversed by systemic naloxone or yohimbine but
with differences to the spinal actions of the same doses (Bee et al.,
2011). These MOR and the NRI components likely enable tapentadol to
be effective with reduced opioid load compared to pure opioids, in that
equivalent analgesia can be produced in animals and patients with less
side-effects (Riemsma et al., 2011; Schug et al., 1992). In patients, there
are also improvements in co-morbidities and quality of life. Thus,
tapentadol, as pregabalin (Gonçalves and Dickenson, 2012), is able to
suppress spinal sensory neuronal activity and modulate AMY function,
the latter likely to be related to the affective components of pain.
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